IS7475A - Þrí-staðgengnir heteróarýlhópar og aðferðir til að smíða og nota slík efni - Google Patents
Þrí-staðgengnir heteróarýlhópar og aðferðir til að smíða og nota slík efniInfo
- Publication number
- IS7475A IS7475A IS7475A IS7475A IS7475A IS 7475 A IS7475 A IS 7475A IS 7475 A IS7475 A IS 7475A IS 7475 A IS7475 A IS 7475A IS 7475 A IS7475 A IS 7475A
- Authority
- IS
- Iceland
- Prior art keywords
- tri
- substances
- making
- methods
- substituted heteroaryl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical class 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36979302P | 2002-04-04 | 2002-04-04 | |
| PCT/US2003/010440 WO2003087304A2 (en) | 2002-04-04 | 2003-04-04 | Tri-substituted heteroaryls and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7475A true IS7475A (is) | 2004-09-28 |
Family
ID=29250467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7475A IS7475A (is) | 2002-04-04 | 2004-09-28 | Þrí-staðgengnir heteróarýlhópar og aðferðir til að smíða og nota slík efni |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7612094B2 (is) |
| EP (1) | EP1499308A4 (is) |
| JP (1) | JP2005527590A (is) |
| KR (1) | KR20040094908A (is) |
| CN (1) | CN100448868C (is) |
| AR (1) | AR039241A1 (is) |
| AU (1) | AU2003228446B2 (is) |
| CA (1) | CA2480860A1 (is) |
| EA (1) | EA010418B1 (is) |
| IL (1) | IL164295A0 (is) |
| IS (1) | IS7475A (is) |
| MX (1) | MXPA04009546A (is) |
| NO (1) | NO20044779L (is) |
| NZ (1) | NZ536202A (is) |
| PL (1) | PL373502A1 (is) |
| RS (1) | RS95904A (is) |
| UA (1) | UA81624C2 (is) |
| WO (1) | WO2003087304A2 (is) |
| ZA (1) | ZA200407902B (is) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| GB0217787D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | C ompounds |
| MXPA05002332A (es) | 2002-09-18 | 2005-06-08 | Pfizer Prod Inc | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf). |
| KR20050057441A (ko) | 2002-09-18 | 2005-06-16 | 화이자 프로덕츠 인코포레이티드 | 전환 성장 인자 억제제로서의 신규한 아이소티아졸 및아이속사졸 화합물 |
| WO2004026306A2 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| CN1681805A (zh) | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物 |
| JP2006502236A (ja) | 2002-09-18 | 2006-01-19 | ファイザー・プロダクツ・インク | 形質転換成長因子（ｔｇｆ）阻害剤としてのトリアゾール誘導体 |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| CA2551524A1 (en) * | 2003-12-24 | 2005-07-21 | Scios, Inc. | Treatment of malignant gliomas with tgf-beta inhibitors |
| NZ549003A (en) * | 2004-03-05 | 2009-07-31 | Taisho Pharmaceutical Co Ltd | Thiazole derivative as an ALK5 inhibitor |
| US20080319012A1 (en) | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| JP2008511631A (ja) * | 2004-08-31 | 2008-04-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール |
| US20070275968A1 (en) * | 2004-09-07 | 2007-11-29 | Hitoshi Kurata | Substituted Biphenyl Derivative |
| US7297816B2 (en) | 2004-09-24 | 2007-11-20 | Janssen Pharmaceutica N.V. | Sulfonamide compounds |
| AU2005295734A1 (en) * | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| EP1973914A2 (en) | 2005-12-22 | 2008-10-01 | Biogen Idec MA Inc. | Transforming growth factor modulators |
| CN101553254A (zh) | 2006-10-03 | 2009-10-07 | 建新公司 | TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途 |
| WO2009009059A1 (en) * | 2007-07-09 | 2009-01-15 | Biogen Idec Ma Inc. | Spiro compounds as antagonists of tgf-beta |
| US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| WO2009115572A2 (en) * | 2008-03-21 | 2009-09-24 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| CL2009000904A1 (es) * | 2008-04-21 | 2010-04-30 | Shionogi & Co | Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende. |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EP2285380A4 (en) * | 2008-05-30 | 2012-03-14 | Summa Health Systems Llc | METHOD OF USE OF TGF-B RECEPTOR INHIBITORS OR ACTIVIN-LIKE KINASE (ALK) -5-HEMMER A-83-01 AND SB-431542 FOR THE TREATMENT OF EYE DISEASES AND WOUND HEALING TREATMENTS |
| WO2010011917A1 (en) * | 2008-07-25 | 2010-01-28 | Glaxosmithkline Llc | SEH AND 11β-HSD1 DUAL INHIBITORS |
| US20100267731A1 (en) * | 2009-04-17 | 2010-10-21 | Summa Health Systems, LLC | Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring |
| US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| RU2612958C2 (ru) | 2011-07-13 | 2017-03-14 | Ск Кемикалз Ко., Лтд. | 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4 |
| WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
| US9468612B2 (en) | 2011-10-26 | 2016-10-18 | Seattle Children's Hospital | Cysteamine in the treatment of fibrotic disease |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| PT2970205T (pt) | 2013-03-14 | 2019-08-26 | Tolero Pharmaceuticals Inc | Inibidores da jak2 e da alk2 e métodos para a sua utilização |
| US10842794B2 (en) | 2014-02-07 | 2020-11-24 | Támogatott Kutatócsoportok Irodája | Use of Sigma-1 receptor agonist compounds |
| WO2015118365A1 (en) | 2014-02-07 | 2015-08-13 | Mta Támogatott Kutatócsoportok Irodája | Novel use of sigma-1 receptor agonist compounds |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| WO2018203219A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| US20210154188A1 (en) * | 2018-04-02 | 2021-05-27 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
| CA3126689C (en) * | 2019-01-22 | 2023-10-03 | Bisichem Co., Ltd. | A fused ring heteroaryl compound as an alk4/5 inhibitor |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| CN115052663B (zh) | 2020-01-08 | 2026-06-09 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
| EP4182323B1 (en) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine amino derivatives as alk5 inhibitors |
| PT4182308T (pt) | 2020-07-15 | 2024-12-04 | Chiesi Farm Spa | Derivados de piridazinil amino como inibidores de alk5 |
| EP4182322B1 (en) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| WO2022136221A1 (en) | 2020-12-23 | 2022-06-30 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| CN112759592A (zh) * | 2021-02-01 | 2021-05-07 | 无锡鸣鹭医药科技有限公司 | 一种6-碘[1,2,3]三唑并[1,5-a]吡啶的合成方法 |
| CN114105975A (zh) * | 2021-02-25 | 2022-03-01 | 无锡海伦生物科技有限公司 | 一种[1,2,4]三氮唑[1,5-a]吡啶-6-甲醛的合成方法 |
| CA3232178A1 (en) | 2021-09-21 | 2023-03-30 | Daniela PIZZIRANI | Pyridazinyl amino derivatives as alk5 inhibitors |
| US20250270215A1 (en) | 2022-04-27 | 2025-08-28 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
| WO2024111626A1 (ja) * | 2022-11-25 | 2024-05-30 | カルナバイオサイエンス株式会社 | 新規チアゾール誘導体 |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| CN121181544A (zh) * | 2025-07-07 | 2025-12-23 | 无锡海伦生物科技有限公司 | 一种三唑并吡啶化合物的制备方法 |
Family Cites Families (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940486A (en) | 1971-05-10 | 1976-02-24 | Ciba-Geigy Corporation | Imidazole derivatives in the treatment of pain |
| DE3029376A1 (de) | 1980-07-31 | 1982-03-18 | Nepera Chemical Co. Inc., Harriman, N.Y. | Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen |
| US4302464A (en) | 1980-10-16 | 1981-11-24 | Pfizer Inc. | Imidazolylpyridine therapeutic agents |
| JPH01181187U (is) | 1988-06-13 | 1989-12-27 | ||
| DE68925011T2 (de) | 1988-09-16 | 1996-06-27 | Philips Electronics Nv | Hochauflösungs-Fersehsystem. |
| JPH02216969A (ja) | 1989-02-16 | 1990-08-29 | Nec Corp | ファクシミリ端末 |
| WO1992016527A1 (fr) | 1991-03-22 | 1992-10-01 | Nippon Soda Co., Ltd. | Derive de pyridine substitue en position 2, sa production, et bactericide d'agrohorticulture |
| US5916891A (en) | 1992-01-13 | 1999-06-29 | Smithkline Beecham Corporation | Pyrimidinyl imidazoles |
| IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
| US5656644A (en) | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| DK64592D0 (da) * | 1992-05-14 | 1992-05-14 | Carlbiotech Ltd As | Peptider til terapeutisk behandling |
| US5593991A (en) | 1993-07-16 | 1997-01-14 | Adams; Jerry L. | Imidazole compounds, use and process of making |
| US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
| IL110296A (en) | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| US5670527A (en) | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
| AU7629594A (en) | 1993-07-21 | 1995-02-20 | Smithkline Beecham Corporation | Imidazoles for treating cytokine mediated disease |
| US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
| GB9423460D0 (en) | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
| ATE252094T1 (de) | 1994-12-13 | 2003-11-15 | Hoffmann La Roche | Imidazol derivate mit proteinkinase, insbesondere egf-r tyrosinkinase, inhibierender wirkung |
| JP3734180B2 (ja) | 1994-12-28 | 2006-01-11 | エーザイ株式会社 | 新規ピラゾール誘導体 |
| US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| IL118544A (en) | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
| US6369068B1 (en) | 1995-06-07 | 2002-04-09 | Smithkline Beecham Corporation | Amino substituted pyrimidine containing compounds |
| US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
| US5854276A (en) | 1995-06-29 | 1998-12-29 | Fujisawa Pharmaceutical Co., Ltd. | Substance WF16616, process for production thereof, and use thereof |
| US5837719A (en) | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
| US5792778A (en) | 1995-08-10 | 1998-08-11 | Merck & Co., Inc. | 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| US6083949A (en) | 1995-10-06 | 2000-07-04 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| AU7482396A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
| AU7529096A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
| ZA9610687B (en) | 1995-12-22 | 1997-09-29 | Smithkline Beecham Corp | Novel synthesis. |
| ZA97175B (en) | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
| US5756499A (en) | 1996-01-11 | 1998-05-26 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US6046208A (en) | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| WO1997028160A1 (en) | 1996-02-01 | 1997-08-07 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| EP1005343A4 (en) | 1996-03-08 | 2000-06-07 | Smithkline Beecham Corp | USE OF CSAIDS AS ANGIOGENESIS INHIBITORS |
| US6096748A (en) | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
| WO1997035855A1 (en) | 1996-03-25 | 1997-10-02 | Smithkline Beecham Corporation | Novel treatment for cns injuries |
| WO1997035856A1 (en) | 1996-03-25 | 1997-10-02 | Smithkline Beecham Corporation | Novel treatment for cns injuries |
| DE19613172A1 (de) | 1996-04-02 | 1997-10-09 | Bayer Ag | Verwendung von substituierten Aryl-imidazolen |
| US5854265A (en) | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| US5939557A (en) | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| US5872136A (en) | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| US6080870A (en) | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| AU708883B2 (en) | 1996-06-10 | 1999-08-12 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| US5854264A (en) | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| HUP9903330A2 (hu) | 1996-11-19 | 2000-03-28 | Amgen Inc. | Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| HUP0002842A3 (en) | 1997-04-24 | 2002-01-28 | Ortho Mcneil Pharm Inc | Substituted imidazoles, process for producing them, pharmaceutical compositions containing them, their use and their intermediates |
| US5932576A (en) | 1997-05-22 | 1999-08-03 | G. D. Searle & Company | 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
| US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
| AU742293B2 (en) | 1997-06-12 | 2001-12-20 | Aventis Pharma Limited | Imidazolyl-cyclic acetals |
| US20020156104A1 (en) | 1997-06-13 | 2002-10-24 | Jerry L. Adams | Novel pyrazole and pyrazoline substituted compounds |
| JP2002505690A (ja) | 1997-06-19 | 2002-02-19 | スミスクライン・ビーチャム・コーポレイション | 新規なアリールオキシピリミジン置換イミダゾール化合物 |
| AU8757098A (en) | 1997-06-30 | 1999-02-10 | Ortho-Mcneil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
| US6562832B1 (en) | 1997-07-02 | 2003-05-13 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| AU8351498A (en) | 1997-07-17 | 1999-02-10 | William Harvey Research Limited | Use of adenosine tri- or tetra-phosphates and their analogues for the reatment of cerebral infarction |
| EP1021173A1 (en) | 1997-10-10 | 2000-07-26 | Imperial College Innovations Limited | Use of csaid?tm compounds for the management of uterine contractions |
| JP2001526230A (ja) | 1997-12-19 | 2001-12-18 | スミスクライン・ビーチャム・コーポレイション | ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用 |
| GB9809869D0 (en) | 1998-05-09 | 1998-07-08 | Medical Res Council | Inhibition of protein kinases |
| BR9910621A (pt) | 1998-05-22 | 2001-01-30 | Smithkline Beecham Corp | Novos compostos de imidazol 2-alquil substituìdos |
| AU4395399A (en) | 1998-07-02 | 2000-01-24 | Sankyo Company Limited | Five-membered heteroaryl compounds |
| ES2221426T3 (es) | 1998-08-20 | 2004-12-16 | Smithkline Beecham Corporation | Nuevos compuestos de triazol sustituidos. |
| WO2000023444A1 (en) * | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| WO2000026209A1 (en) | 1998-11-03 | 2000-05-11 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
| US6548503B1 (en) | 1998-11-04 | 2003-04-15 | Smithkline Beecham Corporation | Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| US6239279B1 (en) | 1998-12-16 | 2001-05-29 | Smithkline Beecham Corporation | Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives |
| US6288089B1 (en) | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| KR100711538B1 (ko) | 1998-12-25 | 2007-04-27 | 아스카 세이야쿠 가부시키가이샤 | 아미노피라졸 유도체 |
| CA2368630A1 (en) | 1999-04-02 | 2000-10-12 | Ruth R. Wexler | Aryl sulfonyls as factor xa inhibitors |
| AU4798000A (en) * | 1999-04-09 | 2000-11-14 | Smithkline Beecham Corporation | Triarylimidazoles |
| CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
| CN1281604C (zh) | 1999-06-03 | 2006-10-25 | 帝国脏器制药株式会社 | 取代吡唑化合物 |
| DE60027431T2 (de) | 1999-07-02 | 2007-07-12 | Stuart A. Rancho Santa Fe Lipton | Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten |
| WO2001022965A1 (en) | 1999-09-28 | 2001-04-05 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| CA2395564A1 (en) | 1999-11-22 | 2001-05-31 | Smithkline Beecham Plc | Novel compounds |
| US20030109428A1 (en) | 1999-12-01 | 2003-06-12 | John Bertin | Novel molecules of the card-related protein family and uses thereof |
| US6610688B2 (en) | 1999-12-21 | 2003-08-26 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| EP1263753B1 (en) | 2000-03-06 | 2004-05-06 | SmithKline Beecham plc | Imidazol derivatives as raf kinase inhibitors |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| GB0011092D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (III) |
| EP1289523A1 (en) | 2000-06-01 | 2003-03-12 | Merck & Co., Inc. | Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors |
| AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| WO2002024680A1 (en) | 2000-09-21 | 2002-03-28 | Smithkline Beecham P.L.C. | Imidazole derivatives as raf kinase inhibitors |
| US6755497B2 (en) * | 2000-09-26 | 2004-06-29 | Canon Kabushiki Kaisha | Ink-jet printing apparatus, control method thereof, and data processing apparatus and method |
| JP2002114780A (ja) | 2000-10-11 | 2002-04-16 | Taisho Pharmaceut Co Ltd | ４−（３−インドリル）イミダゾール誘導体 |
| JP2004511554A (ja) | 2000-10-18 | 2004-04-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 炎症性疾患の治療で有用な置換イミダゾール |
| US6630325B1 (en) | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
| EP1349851A4 (en) | 2000-11-16 | 2004-09-08 | Smithkline Beecham Corp | COMPOUNDS |
| GB0027987D0 (en) | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| ES2289004T3 (es) | 2000-11-20 | 2008-02-01 | Smithkline Beecham Corporation | Nuevos compuestos. |
| GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| WO2002062787A1 (en) | 2001-02-02 | 2002-08-15 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
| GB0102668D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| GB0102673D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| ATE291020T1 (de) | 2001-02-02 | 2005-04-15 | Smithkline Beecham Corp | Pyrazolderivate gegen tgf überexprimierung |
| GB0102672D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| GB0102665D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| ITMI20010821A1 (it) | 2001-04-17 | 2002-10-17 | Gienne Pharma S P A | Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco |
| EP2048142A3 (en) | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| JP2004532234A (ja) | 2001-04-27 | 2004-10-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | トリアゾール由来キナーゼインヒビターおよびその使用 |
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| US6727364B2 (en) | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| JP2005022972A (ja) | 2001-05-16 | 2005-01-27 | Teikoku Hormone Mfg Co Ltd | ４−（４−ピリダジニル）ピラゾール誘導体 |
| WO2002098365A2 (en) * | 2001-06-07 | 2002-12-12 | Skinmedica, Inc. | Conditioned cell culture media and uses thereof |
| US7300442B2 (en) * | 2001-07-11 | 2007-11-27 | Daniel Cherfas | Method of destroying formations in a body |
| WO2003015781A1 (en) | 2001-08-15 | 2003-02-27 | Sankyo Company, Limited | Novel antidiabetic pharmaceutical compositions |
| GB0127433D0 (en) | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| WO2003050120A1 (en) | 2001-12-11 | 2003-06-19 | Smithkline Beecham Corporation | Pyrazolo-pyridine derivatives as antiherpes agents |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| AU2003230829B8 (en) | 2002-04-26 | 2008-12-11 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
| AU2003229305A1 (en) | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0217786D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| GB0217783D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| GB0217780D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| EP1539748A1 (en) | 2002-07-31 | 2005-06-15 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| CN1681805A (zh) | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物 |
| JP2006502236A (ja) | 2002-09-18 | 2006-01-19 | ファイザー・プロダクツ・インク | 形質転換成長因子（ｔｇｆ）阻害剤としてのトリアゾール誘導体 |
| MXPA05002332A (es) | 2002-09-18 | 2005-06-08 | Pfizer Prod Inc | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf). |
| CN100519552C (zh) | 2002-09-25 | 2009-07-29 | 宇部兴产株式会社 | 吡唑化合物 |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| AU2003300099A1 (en) | 2003-01-02 | 2004-07-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta |
| WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| GB0313915D0 (en) | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
| GB0313914D0 (en) | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
-
2003
- 2003-04-03 AR ARP030101166A patent/AR039241A1/es unknown
- 2003-04-04 KR KR10-2004-7015706A patent/KR20040094908A/ko not_active Ceased
- 2003-04-04 NZ NZ536202A patent/NZ536202A/en not_active IP Right Cessation
- 2003-04-04 CA CA002480860A patent/CA2480860A1/en not_active Abandoned
- 2003-04-04 UA UA20041108993A patent/UA81624C2/ru unknown
- 2003-04-04 JP JP2003584248A patent/JP2005527590A/ja active Pending
- 2003-04-04 CN CNB038126990A patent/CN100448868C/zh not_active Expired - Fee Related
- 2003-04-04 US US10/510,459 patent/US7612094B2/en not_active Expired - Lifetime
- 2003-04-04 WO PCT/US2003/010440 patent/WO2003087304A2/en not_active Ceased
- 2003-04-04 EP EP03726198A patent/EP1499308A4/en not_active Withdrawn
- 2003-04-04 PL PL03373502A patent/PL373502A1/xx not_active Application Discontinuation
- 2003-04-04 RS YU95904A patent/RS95904A/sr unknown
- 2003-04-04 AU AU2003228446A patent/AU2003228446B2/en not_active Ceased
- 2003-04-04 MX MXPA04009546A patent/MXPA04009546A/es unknown
- 2003-04-04 EA EA200401309A patent/EA010418B1/ru not_active IP Right Cessation
- 2003-04-04 IL IL16429503A patent/IL164295A0/xx unknown
-
2004
- 2004-09-28 IS IS7475A patent/IS7475A/is unknown
- 2004-09-30 ZA ZA200407902A patent/ZA200407902B/en unknown
- 2004-11-03 NO NO20044779A patent/NO20044779L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UA81624C2 (ru) | 2008-01-25 |
| NO20044779L (no) | 2005-01-04 |
| AU2003228446A1 (en) | 2003-10-27 |
| JP2005527590A (ja) | 2005-09-15 |
| RS95904A (sr) | 2006-10-27 |
| CN100448868C (zh) | 2009-01-07 |
| US20060063809A1 (en) | 2006-03-23 |
| EP1499308A2 (en) | 2005-01-26 |
| US7612094B2 (en) | 2009-11-03 |
| CA2480860A1 (en) | 2003-10-23 |
| EA200401309A1 (ru) | 2005-08-25 |
| NZ536202A (en) | 2009-08-28 |
| MXPA04009546A (es) | 2005-01-25 |
| KR20040094908A (ko) | 2004-11-10 |
| WO2003087304A3 (en) | 2004-07-22 |
| EP1499308A4 (en) | 2006-05-24 |
| WO2003087304A2 (en) | 2003-10-23 |
| AU2003228446B2 (en) | 2009-08-06 |
| EA010418B1 (ru) | 2008-08-29 |
| ZA200407902B (en) | 2005-09-22 |
| IL164295A0 (en) | 2005-12-18 |
| AR039241A1 (es) | 2005-02-16 |
| CN1658866A (zh) | 2005-08-24 |
| PL373502A1 (en) | 2005-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7369A (is) | Aðferð og tæki til örflögunýmyndunar | |
| IS8204A (is) | Tæki og aðferð til að hluta niður | |
| NO20032220D0 (no) | Löfteverktöy II og fremgangsmåte for anvendelse av samme | |
| NO20040640L (no) | Anordning og fremgangsmate | |
| NO20055018D0 (no) | Anti-amyolide antistoffer, sammensetninger, fremgangsmater og anvendelser | |
| DK1620551T3 (da) | Phospholipase og fremgangsmåde til fremstilling deraf | |
| DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
| DK1532569T3 (da) | Fremgangsmåde og indretning til kodning af genstande | |
| NO20032993D0 (no) | System og fremgangsmåte for å assosiere egenskaper til objekter | |
| DK1608445T3 (da) | Konfigurationer og fremgangsmåder til kulstofindfangning | |
| NO20044915L (no) | C-aryl-glukosid SGLT2 inhibitorer og metode | |
| DK1628749T3 (da) | Anordninger og fremgangsmåder til biomateriel produktion | |
| NO20054789D0 (no) | Sammensetninger inneholdende piperaciliin og tazobactam nytting for injeksjon | |
| NO20030734L (no) | Anordninger ved testplugg og tetningssystem | |
| DK1715893T3 (da) | Direkte kompressionsformulering og fremgangsmåde | |
| DK1510492T3 (da) | Fremgangsmåde til afprövning af et elevatoranlæg og elevatoranlæg | |
| DK1682351T3 (da) | Fremgangsmåde og indretning til kombinationstryk | |
| IS7726A (is) | Pyrazólólpyridín og aðferðir til þess að búa þau til og nota | |
| FI20020757A0 (fi) | Suihkutusmenetelmä ja -laitteisto | |
| DK1670823T3 (da) | Kimært mhc-protein og oligomer deraf til specifik målretning | |
| NO20035562L (no) | System og fremgangsmate for forenklet initiering av konferanser | |
| DK1756536T3 (da) | Fremgangsmåde og system til vurdering af prøver | |
| DK1601744T3 (da) | Forgasningsapparat og fremgangsmåde | |
| NO20055778D0 (no) | Folgesystem og assosiert fremgangsmate | |
| NO20043002L (no) | Anordning og fremgangsmate til diskontinuerlig polykondensasjon |